We are proud to announce that the scientific rationale and identification of our newly patented strain, Limosilactobacillus reuteri BG-R46®, has been published in the prestigious journal, Beneficial Microbes. This next-generation strain will be featured in our upcoming baby drops product.
Developed by BioGaia AB (NASDAQ: BIOG) and a research team at the Swedish University of Agricultural Sciences in Uppsala, led by Prof. Stefan Roos, who also oversees BioGaia’s preclinical studies. BG-R46® is an evolved derivative of L. reuteri DSM 17938, obtained through selective exposure to bile, a major stressor in the infant gastrointestinal tract. This process yielded a strain with significantly enhanced bile tolerance, a trait that supports improved survival and colonization in the gut.
In addition to its resilience, L. reuteri BG-R46® demonstrates potentiated production of adenosine, a powerful signaling molecule known for its anti-inflammatory properties and broader physiological roles. Notably, the enzyme 5’-nucleotidase, responsible for adenosine synthesis, was found to be upregulated in large-scale production batches of BG-R46®, indicating robust bioactivity.
The publication outlines comprehensive genomic, phenotypic, and human safety assessments, confirming that BG-R46® is a biologically distinct, well-characterized, and safe strain for human use. It also builds on previous findings that BG-R46® produces extracellular membrane vesicles with enhanced functional properties1.
This milestone reinforces our commitment to advancing microbiome science, delivering clinically validated probiotic solutions, and maintaining our position as both a global leader in the field and a trusted brand among consumers and healthcare professionals.
1 Extracellular membrane vesicles from Limosilactobacillus reuteri strengthen the intestinal epithelial integrity, modulate cytokine responses and antagonize activation of TRPV1.
Pang Y, Ermann Lundberg L, Mata Forsberg M, Ahl D, Bysell H, Pallin A, Sverremark-Ekström E, Karlsson R, Jonsson H, Roos S.
Front Microbiol. 2022 Nov 17;13:1032202. doi: 10.3389/fmicb.2022.1032202. eCollection 2022. PMID: 36466671
Study reference: https://brill.com/view/journals/bm/aop/article-10.1163-18762891-bja00101/article-10.1163-18762891-bja00101.xml?ebody=full%20html-copy1
Innovations in Food (& Beverage) Technology is a quarterly magazine distributed globally both in Print and Digital formats. www.innovationsfood.com. Twitter: @Innovfoodtech. Instagram: @innovationsinfoodtechnology. Linkedin: www.linkedin.com/in/terry-prior52
